Kim G, Lim S, Kwon HS, et al. - In patients with type 2 diabetes mellitus (T2DM), researchers tested the safety and effectiveness of evogliptin compared with linagliptin. For this investigation, patients (n = 207) with T2DM who had HbA1c levels of 7.0–10.0% were randomized 1:1 to receive evogliptin 5 mg (n = 102) or linagliptin 5 mg (n = 105) daily for 12 weeks. Findings revealed that the mean changes in HbA1c in the evogliptin group and the linagliptin group were − 0.85% and − 0.75%, respectively, after 12 weeks of treatment. According to this 12‐week multicenter, randomized, double‐blind, active‐controlled, and 12‐week open‐label extension study, evogliptin's glucose‐lowering efficacy was non‐inferior to linagliptin. It was sustained at week 24 with a 0.94% decrease in HbA1c. Evogliptin therapy improved glycemic variability in patients with T2DM without causing any serious adverse events.